retatrutide clinical trial weight loss data Lilly's triple agonist achieves 16.8% in phase 3 Retatrutide Starting Dose: What Clinical

Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

These trade-offs will likely inform how clinicians and the FDA approach the final approved dose range

Brain aging in a population-based context

This is usually the positive inotropic effect (stronger contractions) rather than an arrhythmia, but it can be unsettling if you are not expecting it